ClinicalTrials.gg
CompletedNCT00739934Updated Jan 28, 2011Results posted

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

A Phase 2 interventional study of voriconazole (Vfend) in Candidiasis and Candidemia, sponsored by Pfizer. Completed at 14 sites in United States. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2011-01-28.

Primary conditionCandidemiaRegistry: CandidiasisReclassifiedWhy we changed it
Registry
Candidiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Candidemia
Why
  1. The study's listed conditions name Candidemia, a narrower term within Candidiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Candidemia by Pfizer — none open to participants now, none under way, none of them phase 3. Candidemia · Pfizer.

Enrollment
9th of 12
40 · median 49
Started
2008
with 5 others
Phase 2
2 of 15
none open now
Registered
7th of 15
by date

Among the 15 studies in Candidemia by Pfizer, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 6 that started in 2008, is one of 2 in phase 2, and was the 7th registered.

Candidemia

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

Browse Candidemia studies →

Open to participants now

None of the 15 studies in Candidemia by Pfizer is open now. The open studies under Candidemia, anywhere →

Who these studies take

Of the 2 Candidemia studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 2 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Candidemia by Pfizer as a file.
02

Study summary

In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down. Since we know the dose in adults, and we think we know the matching doses in the young patients ages 2 to 12 years old, we will compare the amount of drug that goes into the system with what we know works in adults. We give the drug by a needle directly into the blood, then few days later we stop that and give the drug by mouth. Meanwhile, we draw a little bit of blood at certain times to measure the drug in it.

03

Conditions studied

  • Candidiasis
  • Candidemia

Browse trials for

Keywords

  • Open-Label
  • Pharmacokinetics
  • Intravenous to oral switch
  • Safety
  • Voriconazole
  • Immunocompromise
  • Children
  • High Risk For Systemic Fungal Infection.
04

In context

Candidemia Reclassified

73 studies on the registry are indexed under Candidemia; 5 are open to participants now.

This study's enrollment of 40 is below the median of 63 across 44 interventional studies indexed under Candidemia.

Browse Candidemia studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Candidemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Candidiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female from 2 to \<12 years of age.
  • Require treatment for the prevention of systemic fungal infection.
  • Expected to develop neutropenia (ANC \<500 cells/μL) lasting more than 10 days following chemotherapy.
  • Anticipated to live for more than 3 months.

Exclusion criteria

Exclusion Criteria:

  • Evidence of any liver or renal function or other abnormalities such as cardiac arrhythmia, hypokalemia, hypomagnesemia or hypocalcemia.
  • Documented bacterial or viral infection not responding to appropriate treatment.
  • to or severe intolerance of azole antifungal agents.
  • Receiving other azoles or drugs that is are prohibited in the voriconazole label or associated.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Children aged 2 to <12 years

    Immunocompromised children aged 2 to \<12 years who are at high risk for systemic fungal infection.

    Drug: voriconazole (Vfend)

Interventions

  • Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h Notes: 1. If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose. 2. Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30. (IV = Intravenous; POS = Powder for oral suspension)

    Also known as: UK-109,496; Vfend; voriconazole

07

What researchers measure

Primary outcomes

  1. Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  2. Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration

    Time frame: Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  3. Time to Reach Cmax (Tmax) Following IV Administration

    Time frame: Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  4. AUC12,ss Following Oral Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose

  5. Cmax,ss Following Oral Administration

    Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose

  6. Tmax Following Oral Administration

    Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose

Secondary outcomes

  1. AUC12 Following IV Loading Dose

    AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  2. Cmax Following an IV Loading Dose

    Time frame: Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  3. Tmax Following an IV Loading Dose

    Time frame: Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  4. Trough Concentrations (Cmin)

    Time frame: Day 7 (up to Day 20 or more) for IV; Day 7 (or later) for oral at predose

  5. AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  6. Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

    Time frame: Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  7. Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

    Zero Tmax refers to the highest concentration observed for one participant at predose. The profile of the metabolite is relatively flat, which could result in slight variation in sample collection or assay process.

    Time frame: Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose

  8. AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

    AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

    Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose

  9. Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

    Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose

  10. Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

    Time frame: Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose

08

Results

Posted Jan 25, 2011

Participant flow

Voriconazole IV
Participant flow — Voriconazole IV
MilestoneAll Participants
Started40
Completed34
Not completed6
Withdrew: Adverse event6
Voriconazole Oral
Participant flow — Voriconazole Oral
MilestoneAll Participants
Started34
Completed31
Not completed3
Withdrew: Other3

Outcome measures

PrimaryArea Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg*h/mL
Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration
μg*h/mLVoriconazole IV
Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration21.42 ± 35.05
PrimaryPeak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Time frame:
Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg/mL
Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
μg/mLVoriconazole IV
Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration4.26 ± 3.73
PrimaryTime to Reach Cmax (Tmax) Following IV Administration
Time frame:
Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Median · hours
Time to Reach Cmax (Tmax) Following IV Administration
hoursVoriconazole IV
Time to Reach Cmax (Tmax) Following IV Administration2.30 (1.00 to 4.07)
PrimaryAUC12,ss Following Oral Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg*h/mL
AUC12,ss Following Oral Administration
μg*h/mLVoriconazole Oral
AUC12,ss Following Oral Administration18.64 ± 50.63
PrimaryCmax,ss Following Oral Administration
Time frame:
Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg/mL
Cmax,ss Following Oral Administration
μg/mLVoriconazole Oral
Cmax,ss Following Oral Administration3.62 ± 4.66
PrimaryTmax Following Oral Administration
Time frame:
Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Reported as:
Median · hours
Tmax Following Oral Administration
hoursVoriconazole Oral
Tmax Following Oral Administration1.07 (0.73 to 8.03)
SecondaryAUC12 Following IV Loading Dose

AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg*h/mL
AUC12 Following IV Loading Dose
μg*h/mLVoriconazole IV
AUC12 Following IV Loading Dose7.85 ± 6.71
SecondaryCmax Following an IV Loading Dose
Time frame:
Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg/mL
Cmax Following an IV Loading Dose
μg/mLVoriconazole IV
Cmax Following an IV Loading Dose2.15 ± 1.10
SecondaryTmax Following an IV Loading Dose
Time frame:
Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Median · hours
Tmax Following an IV Loading Dose
hoursVoriconazole IV
Tmax Following an IV Loading Dose2.30 (1.72 to 4.08)
SecondaryTrough Concentrations (Cmin)
Time frame:
Day 7 (up to Day 20 or more) for IV; Day 7 (or later) for oral at predose
Reported as:
Geometric mean · μg/mL
Trough Concentrations (Cmin)
μg/mLAll Treatments
IV Day 7 (up to Day 20) (n=36)0.61 ± 2.56
Oral Day 7 (up to Day 30) (n=32)0.52 ± 3.32
SecondaryAUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg*h/mL
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
μg*h/mLVoriconazole IV
Day 120.98 ± 8.05
Day 7 (up to Day 20)41.95 ± 14.30
SecondaryCmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame:
Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg/mL
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
μg/mLVoriconazole IV
Day 12.97 ± 0.94
Day 7 (up to Day 20)4.47 ± 1.44
SecondaryTmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration

Zero Tmax refers to the highest concentration observed for one participant at predose. The profile of the metabolite is relatively flat, which could result in slight variation in sample collection or assay process.

Time frame:
Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose
Reported as:
Median · hours
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
hoursVoriconazole IV
Day 14.00 (1.72 to 8.00)
Day 7 (up to Day 20)4.00 (0.00 to 12.05)
SecondaryAUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration

AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.

Time frame:
Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg*h/mL
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
μg*h/mLVoriconazole Oral
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration51.65 ± 27.88
SecondaryCmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame:
Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Reported as:
Geometric mean · μg/mL
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
μg/mLVoriconazole Oral
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration5.62 ± 2.54
SecondaryTmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame:
Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose
Reported as:
Median · hours
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
hoursVoriconazole Oral
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration3.97 (0.92 to 8.03)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole IV—6/40 (15%)39/40 (97.5%)
Voriconazole Oral—13/34 (38.2%)34/34 (100%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventVoriconazole IVVoriconazole Oral
PyrexiaGeneral disorders1/405/34
Abdominal painGastrointestinal disorders0/401/34
DiarrhoeaGastrointestinal disorders0/401/34
Catheter related complicationGeneral disorders0/401/34
Acute graft versus host disease in skinImmune system disorders0/401/34
Central line infectionInfections and infestations0/401/34
Cytomegalovirus infectionInfections and infestations0/401/34
Enterobacter bacteraemiaInfections and infestations0/401/34
Enterobacter sepsisInfections and infestations0/401/34
Transplant failureInjury, poisoning and procedural complications0/401/34
Most frequent other events
Showing 10 of 239
Most frequent other events
EventVoriconazole IVVoriconazole Oral
Mucosal inflammationGeneral disorders20/4011/34
PyrexiaGeneral disorders15/4011/34
HypertensionVascular disorders13/4010/34
PruritusSkin and subcutaneous tissue disorders12/4010/34
Abdominal painGastrointestinal disorders9/409/34
RashSkin and subcutaneous tissue disorders8/409/34
Alanine aminotransferase increasedInvestigations6/408/34
ConstipationGastrointestinal disorders5/407/34
Aspartate aminotransferase increasedInvestigations5/407/34
AlopeciaSkin and subcutaneous tissue disorders6/407/34

Baseline characteristics

Age, Customized
Age, Customized(Participants)All Participants
2 to <6 years24
6 to <12 years16
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female17
Male23
09

Study locations

14 sites
  • Pfizer Investigational Site
    Tucson, Arizona 85719, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85724, United States
  • Pfizer Investigational Site
    Orange, California 92868, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32207, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30322-1062, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30322, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30342-1600, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70118, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21215, United States
  • Pfizer Investigational Site
    Durham, North Carolina 27710, United States
  • Pfizer Investigational Site
    Cleveland, Ohio 44106, United States
  • Pfizer Investigational Site
    Portland, Oregon 97239, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37232, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2008
First posted
Aug 22, 2008
Start
Dec 2008
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Jan 25, 2011
Last update
Jan 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00739934
Lead sponsor
Pfizer
First posted
Aug 22, 2008
Start date
Dec 2008
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Jan 25, 2011
Last update
Jan 28, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion